Recently, the Shenzhen Stock Exchange issued a letter of concern on Shandong Sinobioway Biomedicine Co.Ltd(002581) the company department’s letter of concern [2022] No. 177. Recently, the second Department of management of listed companies has received many complaints from investors, reflecting that no one answered the external consultation telephone of Shandong Sinobioway Biomedicine Co.Ltd(002581) (hereinafter referred to as ” Shandong Sinobioway Biomedicine Co.Ltd(002581) “, Shandong Sinobioway Biomedicine Co.Ltd(002581) . SZ). In addition, the second Department of management of listed companies is concerned that Shandong Sinobioway Biomedicine Co.Ltd(002581) has not yet hired the 2021 annual audit accountant. If the audited annual report is not disclosed within the statutory time limit, there will be a risk of termination of listing of Shandong Sinobioway Biomedicine Co.Ltd(002581) shares.
Please Shandong Sinobioway Biomedicine Co.Ltd(002581) conduct self-examination and explanation on the problem of answering the consultation telephone, explain the progress of employing the 2021 annual audit accountant and fully remind the risk. Please Shandong Sinobioway Biomedicine Co.Ltd(002581) submit relevant explanatory materials to the second Department of management of listed companies for disclosure before March 25, 2022, and send a copy to the dispatched office at the same time.
Shandong Sinobioway Biomedicine Co.Ltd(002581) (hereinafter referred to as ” Shandong Sinobioway Biomedicine Co.Ltd(002581) “) is a public A-share company listed on Shenzhen Stock Exchange controlled by unnamed group. The securities abbreviation is Shandong Sinobioway Biomedicine Co.Ltd(002581) , and the securities code is Shandong Sinobioway Biomedicine Co.Ltd(002581) The company was renamed as “former Zibo Wanchang Technology Co., Ltd.” after major asset restructuring on October 19, 2015.
According to the Securities Daily, on the evening of January 26 this year, Shandong Sinobioway Biomedicine Co.Ltd(002581) disclosed many announcements, including the performance forecast for 2021. Although the company expects to achieve a net profit of 235 million yuan to 352 million yuan attributable to shareholders of Listed Companies in 2021, turning losses into profits. However, the company also said that since the company has not determined the accounting firm to audit the 2021 annual report, it has not pre communicated with the accounting firm on matters related to the performance forecast. On the same day, the company received a letter of concern from Shenzhen Stock Exchange, reminding the company to hire an audit institution as soon as possible in accordance with relevant regulations, actively cooperate and disclose the annual report on schedule.
The following is the original text:
Letter of concern about Shandong Sinobioway Biomedicine Co.Ltd(002581)
Company Department attention letter [2022] No. 177
Shandong Sinobioway Biomedicine Co.Ltd(002581) board of directors:
Recently, our department has received many complaints from investors, reflecting that your company’s external consultation telephone has not been answered. In addition, our department is concerned that at present, your company has not hired the 2021 annual audit accountant. If the audited annual report is not disclosed within the statutory time limit, there will be a risk of termination of listing of your company’s shares.
Your company is requested to conduct self-examination and explanation on the problem of answering the consultation telephone, explain the progress of hiring the 2021 annual audit accountant and fully remind the risk. Your company is requested to submit relevant explanatory materials to our department for disclosure before March 25, 2022, and send a copy to the dispatched office at the same time.
At the same time, remind your company and all directors, supervisors and senior managers to attach great importance to the preparation and disclosure of the 2021 annual report in accordance with the securities law, the measures for the administration of information disclosure of listed companies and other provisions, hire an audit institution as soon as possible, and strictly abide by the securities law, the company law and other laws and regulations, as well as the stock listing rules of the exchange, which are true, accurate, complete, timely Fulfill the obligation of information disclosure fairly and do a good job in the management of investor relations.
We are writing to inform you that
Shenzhen Stock Exchange
Listed company management Department II
March 21, 2022
